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D
uring recent decades, Western populations have experienced a demographic shift toward an elderly population with an increased prevalence of age-related diseases such as myocardial infarction (MI) and dementia. 1, 2 This trend is predicted to intensify, creating economic and public health challenges. 2 Recent advances in managing MI have improved survival rates, 1 further increasing the number of MI survivors. 3 Any associated rise in the incidence of dementia among MI survivors is therefore important to track, with the goal of secondary prevention of dementia after MI.
Putative mechanisms linking MI to increased risk of dementia include chronic hypoperfusion of the brain after MI caused by impaired left ventricular ejection fraction and low blood pressure. 4 Common complications after MI such as atrial fibrillation and hypokinesia of the left ventricle facilitate formation of intracardiac thrombi. The subsequent release of emboli to the brain also could mediate an association with dementia. Consistent with this hypothesis, MI recently was found to be associated with ischemic and hemorrhagic stroke, 5 both of which in turn increase the risk of dementia. 6 In addition, coronary artery bypass grafting (CABG) performed during an MI admission can induce cerebral hypoperfusion during cardioplegia and cerebral embolization after clamping or cannulation of the aorta. 7 Finally, MI and dementia may be independent but convergent diseases caused by common underlying risk factors (eg, diabetes mellitus, hypercholesterolemia, hypertension, and atherosclerosis) but with a longer latency period for dementia.
Only 2 studies have evaluated the risk of all-cause dementia in patients with MI, and their findings have been equivocal. 8, 9 A small cohort study reported a 2-fold higher risk of dementia, but only in men with unrecognized MI (n=159), compared with participants without evidence of previous MI. 8 A small case-control study including 916 cases of dementia and 916 ageand sex-matched controls found no association with preceding MI. 9 In the absence of disease-modifying treatment for most forms of dementia, it is important to identify risk factors with the potential to prevent or delay its onset. We examined the long-term risk of dementia after firsttime MI and the impact of common MI treatments and complications.
METHODS
The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Setting and Design
We conducted this nationwide population-based cohort study in Denmark, which had a cumulative population of 8 262 736 inhabitants during the study period (January 1, 1980-September 1, 2012). The Danish National Health Service provides tax-supported health care, ensuring unfettered access to general practitioners and hospitals for all Danish inhabitants. Accurate linkage of all registries at the individual level is possible in Denmark owing to the unique central personal registry number assigned to each Danish citizen at birth and to residents upon immigration. 10 
Patients With MI
We used the Danish National Patient Registry 11 (DNPR) to identify all patients with a first-time inpatient diagnosis of MI during the study period. The DNPR has recorded information on all admissions to Danish nonpsychiatric hospitals since 1977 and on emergency room and outpatient clinic visits since 1995. 11 Each hospital discharge or outpatient visit is recorded in the DNPR with 1 primary diagnosis and ≥1 secondary diagnoses classified according to the International Classification of Diseases, Eighth Revision (ICD-8) through 1993 and ICD-10 thereafter. 11 We identified patients with MI using both primary and secondary diagnoses.
General Population Comparison Cohort
We created a general population comparison cohort using the Danish Civil Registration System, which has provided daily updates on vital statistics, including dates of birth, emigration, and death, since 1968. 10 For each patient in the MI cohort, 5 individuals from the general population without an MI diagnosis were randomly selected and matched on sex, birth year, and calendar year of MI diagnosis. We used matching with
Clinical Perspective
What Is New?
• Previous studies on the association between myocardial infarction and dementia are scarce and limited by size, equivocal findings, and a sole focus on all-cause dementia.
• In a nationwide population-based cohort including 314 911 patients with myocardial infarction, the risk of vascular dementia was higher compared with a matched general population comparison cohort.
• The risk of vascular dementia was incrementally higher in patients who had stroke or developed severe heart failure during the first year after myocardial infarction and in patients who underwent coronary artery bypass grafting.
• There was no association with all-cause dementia, Alzheimer disease, or other dementia subtypes.
What Are the Clinical Implications?
• Among 1-year survivors of myocardial infarction, attention to the persistently higher risk of vascular dementia is prudent.
• The effect of any formal screening for cognitive decline is unclear.
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replacement (ie, individuals from the general population comparison cohort could be matched with >1 patient with MI).
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The MI admission date was defined as the index date for patients with MI and their matched counterparts in the general population cohort. To ensure capture of only incident cases of dementia, we excluded patients with MI and individuals in the matched comparison cohort who had received a previous diagnosis of dementia, mild cognitive impairment, or an amnestic syndrome, which may represent prodromal dementia. If members of the general population cohort were diagnosed with MI after the index date, follow-up in the comparison cohort was discontinued. They then were transferred to the MI cohort and matched with new members of the general population.
Dementia
Data on inpatient and outpatient dementia diagnoses were retrieved from the DNPR 11 and the Danish Psychiatric Central Research Register. 13 Specifically, we identified Alzheimer disease, vascular dementia, and other dementias (ie, any specified or unspecified dementia other than Alzheimer disease and vascular dementia). In the DNPR, dementia diagnoses are available for hospital admissions since 1977 and for outpatient clinic visits since 1995. 11 The Danish Psychiatric Central Research Register has recorded hospitalizations for dementia since 1969 and outpatient treatment at hospital psychiatric clinics since 1995.
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Covariables
Using patients' medical histories, available in the DNPR since 1977, we obtained information on comorbidities that may represent shared risk factors for MI and dementia. These consisted of all hospital inpatient and outpatient diagnoses of heart failure, angina pectoris, atrial fibrillation/atrial flutter, heart valve disease, hypercholesterolemia, hypertension, stroke, intermittent claudication, obesity, diabetes mellitus, chronic pulmonary disease (as an indicator of chronic smoking), myxedema, alcoholism-related diseases, head trauma, osteoarthritis (as an indicator for use of nonsteroidal anti-inflammatory drugs), anemia, chronic kidney disease, depression, and a modified Charlson Comorbidity Index (CCI) score (excluding congestive heart failure, MI, cerebrovascular disease, dementia, chronic pulmonary disease, diabetes mellitus, and chronic kidney disease from the index). We also obtained information on personal gross income, employment status during the year preceding the index date, and highest education achieved from the Integrated Database for Labor Market Research.
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Surgical Procedures
We obtained information on CABG, percutaneous coronary intervention, and pacemaker implantation from the DNPR, which has coded surgery according to the Danish Classification of Surgical Procedures and Therapies until January 1, 1996, and according to the Nordic Medico-Statistical Committee Classification of Surgical Procedures thereafter.
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Statistical Analyses
We characterized the MI and general population comparison cohorts according to sex, age groups (<60, 60-69, 70-79, and ≥80 years), index year calendar periods (1980-1989, 1990-1999, and 2000-2012) , comorbidities, and socioeconomic status at baseline and at 1 year after MI. We followed up all patients with MI and members of the general population comparison cohort until the occurrence of any dementia diagnosis, emigration, death, or December 31, 2014, whichever came first. A priori, we disregarded the first year after MI and initiated follow-up thereafter because dementia diagnosed shortly after admission for MI is unlikely to be a consequence of MI. The Figure provides a flowchart of exclusions within the first year of MI and the resulting final study population.
We used cumulative incidence functions with death as a competing risk to calculate dementia risks during 1 to 35 years of follow-up. Using multivariable-stratified Cox proportional hazards regression models with censoring at death, we computed hazard ratios (HRs) with 95% confidence intervals (CIs), comparing patients with MI with members of the general population comparison cohort. 15 HRs were controlled for sex, birth year, and calendar year by the matched study design and in multivariable analyses adjusted for preadmission diagnoses of heart failure, stable angina pectoris, atrial fibrillation or atrial flutter, valvular heart disease, hypercholesterolemia, hypertension, stroke, intermittent claudication, obesity, diabetes mellitus, chronic pulmonary disease, myxedema, alcoholism-related disease, head trauma, osteoarthritis, anemia, chronic kidney disease, depression, a modified CCI score, and socioeconomic status (income and employment). The proportional hazards assumption was assessed graphically with log-log plots, and there was no evidence of violation within the follow-up period. The ICD codes used in the study are provided in Tables I and II 
Additional Analyses
To identify clinical pathways with a potential impact on the association between MI and dementia, we stratified by cardiac procedures performed during hospital admissions for MI and by complications occurring between MI and the start of follow-up 1 year later. For heart failure, we performed 2 additional analyses to further examine the impact of increasing severity of post-MI heart failure. First, we examined the impact of increasing daily doses of loop diuretics (furosemide or bumetanide), which previously have been demonstrated to correlate with heart failure mortality. 16 We categorized patients into nonusers (no loop diuretics), low-dose (≤40 mg/d) users, medium-dose (41-80 mg/d) users, and high-dose (≥81 mg/d) users. The daily dose was obtained by multiplying the number of pills across all prescriptions redeemed within the first year after MI by the furosemide-equivalent dose per pill (1 mg bumetanide=80 mg furosemide) 17 and then dividing by 365.25 days. Because the nationwide prescription registry was initiated in 1995, 18 this analysis was restricted to the post-1995 part of the study period. Second, we categorized patients with MI according to the number of inpatient admissions for heart failure during the first year after MI as a proxy for heart failure severity .
The presence of potential interactions was examined in strata of sex, age groups, underlying preadmission comorbidity, and different levels of comorbidity measured with modified CCI scores. We also investigated temporal differences in risk of dementia after MI by splitting up the index periods (1980−1994 and 1995−2012) . In this analysis, we limited follow-up to 10 years to allow sufficient follow-up time for patients in both time periods. We selected these periods because ICD-10 diagnostic codes were introduced in 1994, and outpatient specialist clinic diagnoses became available in 1995. We further stratified the analyses by type of MI diagnosis (primary or secondary) because the positive predictive value is lower (80%) for secondary diagnoses. 19 Because a higher cognitive reserve may modify any association between MI and dementia, 20 we examined the associations by socioeconomic status (income, employment, and education). In the analyses stratified by underlying preadmission comorbidity, modified CCI scores, and socioeconomic status, the matching was dissolved and HRs were additionally adjusted for matching variables. Dissolving the matching introduced a lack of independence among members of the comparison cohort because they were matched with replacement. 12 We therefore used a robust variance estimator in these analyses to account for the lack of independence.
Sensitivity Analyses
We performed several sensitivity analyses. First, given the assumed latency period for development of clinically overt dementia after MI, we repeated the analyses sequentially excluding the initial 2, 3, 5, and 10 years of follow-up. Second, we redefined Alzheimer disease to also include the ICD code for unspecified dementia. Third, we additionally adjusted for education, which was not included in the main analysis because data were unavailable for 43% of participants and because we assumed a strong collinearity with the other socioeconomic factors (income and employment). Fourth, we divided follow-up time into periods of 1 to 10, 11 to 20, and 21 to 35 years to examine whether associations weakened over time. Fifth, we repeated the analyses for subgroups of MI (ST-segment-elevation MI and non-ST-segment-elevation MI). Sixth, we continued follow-up for members of the comparison cohort who experienced an MI during follow-up.
All statistical analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC). The study was approved by the Danish Data Protection Agency (record No. 1-16-02-268-14). According to Danish legislation, no approval from an ethics committee or informed consent from patients is required for registry-based studies in Denmark.
RESULTS
We identified 314 911 patients with a first-time MI and 1 573 193 matched individuals from the general population (median age, 70.3 years; 63% male; Table 1) . One-year survivors numbered 209 754 patients with MI and 1 003 763 individuals from the comparison cohort (Figure I and Table III in the online-only Data Supplement). Median follow-up time was 7.7 years (25th-75th percentile, 4.0-13.1 years) for patients with MI and 9.8 years (25th-75th percentile, 5.2-16.0 years) for members of the comparison cohort. The difference in follow-up time arose mainly from the competing risk of death after MI. All comorbidities were more common among patients with MI than among members of the comparison cohort both at baseline (Table 1) and among 1-year survivors (Table III in the online-only Data Supplement). Patients with MI also had slightly lower income, educational, and employment levels. Table 2 ). The cumulative incidence of all-cause dementia in the MI cohort after 35 years of follow-up was 8.7% (2.8% for Alzheimer disease, 1.6% for vascular ORIGINAL RESEARCH ARTICLE dementia, and 4.5% for other dementias). As a result of the competing risk of death, the cumulative incidence of dementia was consistently higher in the general population comparison cohort than in the MI cohort (Table 2) . We found no association with all-cause dementia (adjusted HR, 1.01; 95% CI, 0.98-1.03) or other dementias (adjusted HR, 0.98; 95% CI, 0.95-1.01) compared with the general population cohort. For Alzheimer disease, the risk was marginally lower (adjusted HR, 0.92; 95% CI, 0.88-0.95), whereas risk of vascular dementia was significantly higher (adjusted HR, 1.35; 95% CI, 1.28-1.43).
Risk of Dementia
Additional Analyses
The incremental risk of vascular dementia was higher in patients who experienced a stroke within 1 year of MI (adjusted HR, 4.48; 95% CI, 3.29-6.12), whereas atrial fibrillation or flutter was associated with only moderately higher risk (adjusted HR, 1.55; 95% CI, 1.28-1.87). The risk of vascular dementia was also accentuated in patients who underwent pacemaker implantation (adjusted HR, 3.38; 95% CI, 1.42-8.06) or CABG (adjusted HR, 3.99; 95% CI, 1.31-12.18) during their MI admission, although CIs were overlapping with the CIs of the main vascular dementia estimate (Table 3 ). Higher risk of vascular dementia was not present in patients with MI undergoing percutaneous coronary intervention during the MI admission and was not associated with the development of hypertension, cardiogenic shock/ pulmonary edema, or unspecified heart failure during the first year after MI. However, the incremental risk of vascular dementia was greater with increasing levels of heart failure severity, as measured by the number of admissions for heart failure during the first year after MI (adjusted HR, 2.24; 95% CI, 1.21-4.14 for ≥3 admissions). This pattern was also present, although less pronounced, for other subtypes of dementia (Table 4) . Among patients with MI who developed symptomatic heart failure, as measured by the need for loop diuretics, the risk of vascular dementia was only slightly higher (adjusted HR, 1.50; 95% CI, 1.11-2.02 for a low daily furosemide-equivalent dose of ≤40 mg and without additional risk for doses >40 mg). In age-stratified analyses, the association was attenuated with increasing age for all dementia subtypes. The risk of vascular dementia remained higher in older age groups, whereas the risks of all-cause dementia (adjusted HR, 0.88; 95% CI, 0.84-0.92), other dementias (adjusted HR, 0.87; 95% CI, 0.81-0.93), and particularly Alzheimer disease (adjusted HR, 0.80; 95% CI, 0.74-0.87) were moderately lower in patients with MI who were ≥80 years of age. The slightly lower risk of Alzheimer disease observed in the overall results and in older age groups was not present in younger age groups (adjusted HR, 1.02; 95% CI, 0.89-1.15 for age <60 years; adjusted HR, 0.96; 95% CI, 0.89-1.04 for age of 60-69 years). For all-cause dementia and other dementias, a positive association was observed for patients with MI who were <60 years of age (adjusted HR, 1.19; 95% CI, 1.11-1.27 for all-cause dementia; adjusted HR, 1.17; 95% CI, 1.07-1.28 for other dementias). No difference was observed between men and women (Table IV in the online-only Data Supplement). Results remained robust in subgroup analyses of cardiac and noncardiac comorbidity and CCI levels (Table V in the online-only Data Supplement). We observed no temporal difference in the association observed during early (1980-1994) versus late (1995-2012) time periods (Table VI in the online-only Data Supplement). In analyses stratified by primary versus secondary diagnoses of MI, the risks of all-cause and vascular dementia were slightly higher for secondary diagnoses (Table VI in the onlineonly Data Supplement). Across levels of income, employment status, and education, results agreed with those of the main analysis (Table VII in the online-only Data Supplement).
Sensitivity Analyses
Results of the sensitivity analyses are presented in Table  VIII in the online-only Data Supplement. The results changed insignificantly when we sequentially excluded the initial 1 to 10 years of follow-up. The results also remained robust when ICD codes for unspecified dementia were included in the definition of Alzheimer disease, when the model was extended to adjust for education, and when the 3 follow-up periods (1-10, 11-20, and 21-35 years) were considered separately. In addition, type of MI (ST-segment-elevation MI/non-STsegment-elevation MI) did not substantially affect the results. Finally, results were consistent when we continued follow-up for members of the population comparison cohort who experienced MI during follow-up (data not shown).
DISCUSSION
In this nationwide matched population-based cohort study with virtually complete follow-up of 209 890 MI survivors for 35 years, we found a higher risk of vascular dementia compared with the general population. The incremental risk was even greater in patients who underwent CABG during their admission for MI or who experienced stroke during the first year after MI. In patients who developed heart failure requiring hospitalization, the association with vascular dementia was moderately strengthened. The risk of CI indicates confidence interval; and HR, hazard ratio. *Age, sex, and calendar year. †Controlled for matching factors by study design and adjusted for heart failure, stable angina pectoris, atrial fibrillation/atrial flutter, valvular heart disease, hypercholesterolemia, myocarditis, cardiomyopathy, hypertension, stroke, intermittent claudication, obesity, diabetes mellitus, chronic pulmonary disease, myxedema, alcoholism-related disease, head trauma, osteoarthritis, anemia, chronic kidney disease, depression, a modified Charlson Comorbidity Index score, income, and employment.
ORIGINAL RESEARCH ARTICLE
Alzheimer disease was marginally lower, whereas we found no association with all-cause dementia. We observed a progressively smaller increment in risk for all subtypes of dementia with increasing age. This was presumably the result of a low absolute risk of dementia in younger age groups in whom the relative association with an MI is stronger. In particular, the attenuation of the risk of vascular dementia with age may reflect that many individuals with a heavy burden of cardiovascular risk factors do not survive to old age. Accordingly, earlier studies have demonstrated that for men, the incidence of vascular dementia is higher in younger age groups, 21 whereas mixed underlying pathologies are more common in older individuals with dementia. 22 Our results did not differ substantially between 1980 to 1994 and 1995 to 2012 despite considerable improvement during the whole study period in the primary and secondary prevention of MI 23 and in diagnostic modalities for Alzheimer disease such as structural magnetic resonance imaging, biomarkers in cerebrospinal fluid, fluorodeoxyglucose positron emission tomography, and amyloid positron emission tomography. 24 Available studies on the association between MI and dementia are few, and results have been equivocal with either no association or a slightly increased risk. 8, 9 In a small cohort study conducted in Rotterdam, 8 participants were classified into groups of recognized MI (n=424), unrecognized MI (n=345), and no MI (n=5578; reference group) on the basis of ECGs at baseline combined with self-reported history of MI. In men, unrecognized MI (n=159) was associated with higher risk of CI, confidence interval; and HR, hazard ratio. *Controlled for matching factors by study design and adjusted for heart failure, stable angina pectoris, atrial fibrillation/atrial flutter, valvular heart disease, hypercholesterolemia, myocarditis, cardiomyopathy, hypertension, stroke, intermittent claudication, obesity, diabetes mellitus, chronic pulmonary disease, myxedema, alcoholism-related disease, head trauma, osteoarthritis, anemia, chronic kidney disease, depression, a modified Charlson Comorbidity Index score, income, and employment.
all-cause dementia (adjusted HR, 2.14; 95% CI, 1.37-3.35). Unrecognized MI also was associated with more cerebral white matter lesions and more frequent brain infarction on magnetic resonance imaging. In women, there was no association between unrecognized MI and risk of all-cause dementia. Recognized MI was not associated with risk of dementia in either sex. Our study did not include unrecognized MI. However, the null result in the Rotterdam study for all-cause dementia in patients with recognized MI is in line with our findings. In a case-control study of 916 patients with dementia in Rochester, MN, no association was found between MI and all-cause dementia (odds ratio, 1.00; 95% CI, 0.62-1.62). 9 In Western societies, Alzheimer disease accounts for approximately half of all dementia cases, and vascular dementia accounts for 20%, 25, 26 a distribution also reflected in our findings (Table 2 ). Previous studies have focused solely on all-cause dementia, 8, 9 disregarding these dominant subtypes despite different underlying pathophysiologies. Thus, Alzheimer disease is characterized by the accumulation of β-amyloid and tau in plaques and tangles, 27 whereas vascular dementia has a cerebrovascular pathology, characterized by strategically located infarctions and hemorrhages. 28 Our finding of higher risk of vascular dementia may point to several mechanisms. Atherosclerosis may be the underlying factor driving the development of MI, ischemic stroke, and, ultimately, vascular dementia, but with a longer latency period for vascular dementia. In support of this assumption, only risk of vascular dementia was higher in our study. MI has been associated with higher risk of both ischemic stroke and hemorrhagic stroke, 5 which, in turn, have been associated with higher risk of all-cause dementia. 6 In our study, we identified stroke as a strong modifier of the association with vascular dementia but without any substantial impact on the association with other dementia subtypes. Ischemic stroke is plausible as a modifier, resulting from emboli after MI. Such emboli may occur when MI is complicated by atrial fibrillation or regional wall motion abnormalities, both of which increase the risk of thrombus formation within the left atrium and ventricle with the possibility of cerebral embolization. Like ischemic stroke, hemorrhagic stroke may lie on the causal pathway to dementia, prompted by the standard regimen of dual antiplatelet therapy (ie, aspirin plus an ADP receptor inhibitor) during the first year after MI, followed by lifelong aspirin treatment. 29 Other potential factors influencing the risk of vascular dementia after MI may include a history of hypertension, especially when complicated by episodes of hypotension. 30 Acute and chronic hypotension after MI may be caused by cardiogenic shock, heart failure, and atrial fibrillation with low or high ventricular rate response. 31 Hypotension can lead to watershed infarctions in the vulnerable border-zone regions of the brain supplied by the major cerebral arteries. 32 The blood supply to these areas is precarious and may become compromised if cerebral perfusion drops, especially if the supplying arteries are stenosed 33 or the aortic root is stiffened. 34 In line with these premises, we found an incrementally higher risk of vascular dementia in patients with symptomatic CI indicates confidence interval; and HR, hazard ratio. *Controlled for matching factors by study design and adjusted for heart failure, stable angina pectoris, atrial fibrillation/atrial flutter, valvular heart disease, hypercholesterolemia, myocarditis, cardiomyopathy, hypertension, stroke, intermittent claudication, obesity, diabetes mellitus, chronic pulmonary disease, myxedema, alcoholism-related disease, head trauma, osteoarthritis, anemia, chronic kidney disease, depression, a modified Charlson Comorbidity Index score, income, and employment.
†Restricted to patients with myocardial infarction who received a diagnosis of heart failure during the first year after myocardial infarction or redeemed at least 1 prescription during their first year after myocardial infarction for a β-blocker and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
heart failure or atrial fibrillation or flutter during their first year after MI. However, the risk of vascular dementia remained largely unchanged when we restricted the analysis to patients with MI with complications of cardiogenic shock or pulmonary edema.
In addition to stroke, we identified CABG performed during admission for MI as a factor strengthening the association with vascular dementia. This may relate to the specific subset of patients with MI for whom CABG is indicated, for example, patients with triple-vessel disease or stenosis involving the left main stem, which indicates more widespread atherosclerotic disease, including cerebral atherosclerosis. It is also well established that CABG is associated with serious, yet common, postoperative neurological deficits and stroke, 35 plausibly increasing the risk of dementia. However, it remains controversial whether CABG itself increases the risk of long-term dementia. 36 In contrast, patients undergoing percutaneous coronary intervention during their hospitalization for MI were not at higher risk of vascular dementia compared with the general population. Patients selected for percutaneous coronary intervention are likely characterized by less generalized atherosclerosis 37, 38 and less risk of procedure-related cerebral embolization compared with patients undergoing CABG. 35 Furthermore, our study period covers the transition during the 1990s from thrombolytic therapy to percutaneous coronary intervention as standard therapy for MI. Compared with percutaneous coronary intervention, thrombolytic therapy increases the risk of hemorrhagic stroke, 39 which in turn is associated with all-cause dementia. 6 This may also underlie the lack of association with vascular dementia observed in patients with MI selected for percutaneous coronary intervention.
Several study strengths and limitations should be considered in the interpretation of our results. An important strength is the size of the study, allowing precise estimates and the ability to examine several possible interactions and mediators of the association between MI and dementia. The population-based design, within the setting of a tax-supported universal healthcare system with complete follow-up of all patients, largely eliminated selection biases. 10 Registration of the MI diagnosis in the DNPR is accurate, with validation studies consistently reporting positive predictive values >90% throughout the study period. 11, 19, 40, 41 The accuracy of the major dementia diagnoses in the DNPR and the Danish Psychiatric Central Research Register is also high (positive predictive value, 86% for all-cause dementia), although lower for dementia subtypes. 42 A concern is the unknown sensitivity of the dementia diagnosis. The sensitivity may be higher in the MI cohort as a result of surveillance bias, which would lead to overestimation of the risk of dementia compared with the general population. Specifically, attention to vascular dementia may be increased in patients with a history of MI and lead to a channeling effect, that is, the possibility that patients with dementia with cardiovascular diseases may be more likely to receive a diagnosis of vascular dementia than other types of dementia. This may explain the marginally decreased risk of Alzheimer disease and may indicate an overestimation of the risk of vascular dementia. However, such a channeling effect was likely small because the slightly decreased risk of Alzheimer disease was present only in older age groups, in whom the risk of vascular dementia concomitantly decreased.
Despite extensive confounder adjustment for sex, age, comorbidities, and socioeconomic status, our study is limited by its observational design. Thus, residual and unmeasured confounding cannot be ruled out. We lacked information on smoking, which is associated with both MI 43 and dementia. 44 However, we adjusted for hospital diagnoses of chronic obstructive pulmonary disease as a proxy measure for long-term smoking exposure. We also lacked information on physical activity and the apolipoprotein E genotype, which are associated with both MI and dementia 45, 46 and hence may contribute in part to the increased risk of vascular dementia observed in our study. Lifestyle in general, however, was indirectly adjusted for by socioeconomic status and lifestyle diseases.
CONCLUSIONS
MI was associated with higher risk of vascular dementia. The lack of an association with Alzheimer disease and other dementias indicates that shared risk factors (eg, atherosclerosis) combined with post-MI procedures and complications leading to stroke may be the driving mechanisms behind the association with vascular dementia.
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